Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

Nature

Volumn 525, Issue 7569, 2015, Pages 380-383

  Prost, Stéphane ^a   Relouzat, Francis ^a   Spentchian, Marc ^b   Ouzegdouh, Yasmine ^a   Saliba, Joseph ^a   Massonnet, Gérald ^c   Beressi, Jean Paul ^b   Verhoeyen, Els ^d,e   Raggueneau, Victoria ^f   Maneglier, Benjamin ^f   Castaigne, Sylvie ^g   Chomienne, Christine ^c   Chrétien, Stany ^a,h   Rousselot, Philippe ^c,g   Leboulch, Philippe ^a,i,j  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^e CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^h CEA   (France)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j MAHIDOL UNIVERSITY   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; IMATINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; STAT5 PROTEIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BENZAMIDE DERIVATIVE; CITED2 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN;

BLOOD; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITOR; MOLECULAR ANALYSIS; MUTATION; PROTEIN; SURVIVAL;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TREATMENT RESPONSE; AGONISTS; CANCER STEM CELL; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZAMIDES; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PIPERAZINES; PPAR GAMMA; PYRIMIDINES; REPRESSOR PROTEINS; STAT5 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; TRANS-ACTIVATORS;

EID: 84942036511     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature15248     Document Type: Article

References (36)

1. Nguyen, L. V., Vanner, R., Dirks, P. & Eaves, C. J. Cancer stem cells: an evolving concept. Nature Rev. Cancer 12, 133-143 (2012).
2. Chomel, J. C. & Turhan, A. G. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2, 713-727 (2011).
3. de Lavallade, H. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26, 3358-3363 (2008).
4. Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396-409 (2011).
5. Hu, C. J., Sataur, A., Wang, L., Chen, H. & Simon, M. C. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1α and HIF-2α. Mol. Biol. Cell 18, 4528-4542 (2007).
6. Du, J. & Yang, Y. C. Cited2 in hematopoietic stem cell function. Curr. Opin. Hematol. 20, 301-307 (2013).
7. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002).
8. + CML cells. Blood 109, 4016-4019 (2007).
9. Copland, M. et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107, 4532-4539 (2006).
10. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
11. Prost, S. et al. Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARγ/STAT5 signaling pathway in macaques. J. Clin. Invest. 118, 1765-1775 (2008).
12. Berria, R. et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin. Pharmacol. Ther. 82, 275-281 (2007).
13. Avagyan, S., Aguilo, F., Kamezaki, K. & Snoeck, H. W. Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-β2 and FLT3 in hematopoiesis. Blood 118, 6078-6086 (2011).
14. Wang, Z., Li, G., Tse, W. & Bunting, K. D. Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood 113, 4856-4865 (2009).
15. Hoelbl, A. et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol. Med. 2, 98-110 (2010).
16. Kieslinger, M. et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 14, 232-244 (2000).
17. Fatrai, S., Wierenga, A. T., Daenen, S. M., Vellenga, E. & Schuringa, J. J. Identification of HIF2α as an important STAT5 target gene in human hematopoietic stem cells. Blood 117, 3320-3330 (2011).
18. Matsumoto, A. et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89, 3148-3154 (1997).
19. Liu, S. et al. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol. Cancer Ther. 13, 1194-1205 (2014).
20. Wang, L., Giannoudis, A., Austin, G. & Clark, R. E. Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. Exp. Hematol. 40, 811-819 (2012).
21. Szanto, A. & Nagy, L. Retinoids potentiate peroxisome proliferator-activated receptor gamma action in differentiation, gene expression, and lipid metabolic processes in developing myeloid cells. Mol. Pharmacol. 67, 1935-1943 (2005).
22. Chen, Y., Haviernik, P., Bunting, K. D. & Yang, Y. C. Cited2 is required for normal hematopoiesis in the murine fetal liver. Blood 110, 2889-2898 (2007).
23. Du, J. et al. HIF-1α deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency. Blood 119, 2789-2798 (2012).
24. Koschmieder, S. & Schemionek, M. Mouse models as tools to understand and study BCR-ABL1 diseases. Am. J. Blood Res. 1, 65-75 (2011).
25. Rousselot, P. et al. Targeting STAT5 expression resulted in molecular response improvement in patients with chronic phase CML treated with imatinib. ASH Annual Meeting Abstracts, (2012).
26. Davies, G. F., Juurlink, B. H. & Harkness, T. A. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des. Devel. Ther. 3, 79-88 (2009).
27. Yuan, H. et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119, 1904-1914 (2012).
28. Pitulis, N., Papageorgiou, E., Tenta, R., Lembessis, P. & Koutsilieris, M. IL-6 and PPARγ signalling in human PC-3 prostate cancer cells. Anticancer Res. 29, 2331-2337 (2009).
29. Chen, Y., Hu, Y., Zhang, H., Peng, C. & Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nature Genet. 41, 783-792 (2009).
30. Kominsky, D. J. et al. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin. Canc. Res. 15, 3442-3450 (2009).
31. Lu, D. & Carson, D. A. Repression of beta-catenin signaling by PPAR gamma ligands. Eur. J. Pharmacol. 636, 198-202 (2010).
32. Ito, K. et al. A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nature Med. 18, 1350-1358 (2012).
33. Gabert, J. et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17, 2318-2357 (2003).
34. Nègre, D. et al. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther. 7, 1613-1623 (2000).
35. Roth, O. et al. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS/MS. Clin. Chim acta. 411, 140-146 (2010).
36. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010).